Literatur
- 1
Allen K J, Gurrin L C, Constantine C C. et al .
Iron-overload-related disease in HFE hereditary hemochromatosis.
N Engl J Med.
2008;
358
221-230
- 2
Bravi F, Bosetti C, Tavani A. et al .
Coffee drinking and hepatocellular carcinoma risk: a meta-analysis.
Hepatology.
2007;
46
430-435
- 3
Cheng B Q, Jia C Q, Liu C T. et al .
Chemoembolization combined with radiofrequency ablation for patients with hepatocellular
carcinoma larger than 3 cm: a randomized controlled trial.
JAMA.
2008;
299
1669-1677
- 4
Dalgard O, Bjoro K, Ring-Larsen H. et al .
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis
C virus genotype 2 or 3 and rapid virological response.
Hepatology.
2008;
47
35-42
- 5
Fernandez J, Navasa M, Planas R. et al .
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome
and improves survival in cirrhosis.
Gastroenterology.
2007;
133
818-824
- 6
Friedrich-Rust M, Ong M F, Martens S. et al .
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.
Gastroenterology.
2008;
134
960-974
- 7
Gerolami R, Moal V, Colson P.
Chronic hepatitis E with cirrhosis in a kidney-transplant recipient.
N Engl J Med.
2008;
358
859-860
- 8
Haagsma E B, van den Berg A P, Porte R J. et al .
Chronic hepatitis E virus infection in liver transplant recipients.
Liver Transpl.
2008;
14
547-553
- 9
Hui C K, Zhang H Y, Bowden S. et al .
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil
monotherapy in the treatment of chronic hepatitis B.
J Hepatol.
2008;
48
714-720
- 10
Jacobson I M.
Combination therapy for chronic hepatitis B: Ready for prime time?.
J Hepatol.
2008;
48
687-691
- 11
Kamar N, Selves J, Mansuy J M. et al .
Hepatitis E virus and chronic hepatitis in organ-transplant recipients.
N Engl J Med.
2008;
358
811-817
- 12
Kim W R, Flamm S L, Di Bisceglie A M. et al .
Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease.
Hepatology.
2008;
47
1363-1370
- 13
Kulik L M, Carr B I, Mulcahy M F. et al .
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without
portal vein thrombosis.
Hepatology.
2008;
47
71-81
- 14
Lai C L, Gane E, Liaw Y F. et al .
Telbivudine versus lamivudine in patients with chronic hepatitis B.
N Engl J Med.
2007;
357
2576-2588
- 15
Lai M, Hyatt B J, Nasser I. et al .
The clinical significance of persistently normal ALT in chronic hepatitis B infection.
J Hepatol.
2007;
47
760-767
- 16
Lampertico P, Vigano M, Manenti E. et al .
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant
hepatitis B patients.
Gastroenterology.
2007;
133
1445-1451
- 17
Larsson S C, Wolk A.
Coffee consumption and risk of liver cancer: a meta-analysis.
Gastroenterology.
2007;
132
1740-1745
- 18
Law M, Maruyama T, Lewis J. et al .
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.
Nat Med.
2008;
14
25-27
- 19
Lin C L, Liao L Y, Liu C J. et al .
Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum
alanine aminotransferase levels.
Hepatology.
2007;
45
1193-1198
- 20
Livraghi T, Meloni F, Di Stasi M. et al .
Sustained complete response and complications rates after radiofrequency ablation
of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment
of choice?.
Hepatology.
2008;
47
82-89
- 21
Llovet J, Rici S, Mazzaferro V. et al .
Randomized phase III trial of sorafenib versus plazebo in patients with advanced hepatocellular
carcinoma.
J Clin Oncol.
2007;
25
LBA1
- 22
Louvet A, Naveau S, Abdelnour M. et al .
The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic
hepatitis treated with steroids.
Hepatology.
2007;
45
1348-1354
- 23
Mangia A, Minerva N, Bacca D. et al .
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized
controlled trial.
Hepatology.
2008;
47
43-50
- 24
McHutchison J G, Dusheiko G, Shiffman M L. et al .
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis
C.
N Engl J Med.
2007;
357
2227-2236
- 25
McMullan L K, Grakoui A, Evans M J. et al .
Evidence for a functional RNA element in the hepatitis C virus core gene.
Proc Natl Acad Sci U S A.
2007;
104
2879-2884
- 26
Naugler W E, Sakurai T, Kim S. et al .
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.
Science.
2007;
317
121-124
- 27
Pedersen I M, Cheng G, Wieland S. et al .
Interferon modulation of cellular microRNAs as an antiviral mechanism.
Nature.
2007;
449
919-922
- 28
Romero-Gomez M, Cordoba J, Jover R. et al .
Value of the critical flicker frequency in patients with minimal hepatic encephalopathy.
Hepatology.
2007;
45
879-885
- 29
Sagir A, Erhardt A, Schmitt M. et al .
Transient elastography is unreliable for detection of cirrhosis in patients with acute
liver damage.
Hepatology.
2008;
47
592-595
- 30
Shaib Y H, El-Serag H B, Nooka A K. et al .
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based
case-control study.
Am J Gastroenterol.
2007;
102
1016-1021
- 31
Sung J J, Lai J Y, Zeuzem S. et al .
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive
chronic hepatitis B.
J Hepatol.
2008;
48
728-735
- 32
Tan J, Degertekin B, Wong S N. et al .
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment
failure to adefovir in the absence of adefovir-resistant mutations.
J Hepatol.
2008;
48
391-398
- 33
Thimme R, Spangenberg H C, Blum H E.
Chronic hepatitis B.
Dtsch Med Wochenschr.
2008;
133
135-138
- 34
Wedemeyer H, Cornberg M, Protzer U. et al .
German guidelines on diagnosis and therapy of hepatitis B.
Dtsch Med Wochenschr.
2007;
132
1775-1782
- 35
Welzel T M, Mellemkjaer L, Gloria G. et al .
Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide
case-control study.
Int J Cancer.
2007;
120
638-641
- 36
Yuen M F, Fong D Y, Wong D K. et al .
Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year
ideal response.
Hepatology.
2007;
46
1695-1703
Prof. Dr. R. Thimme
Abteilung Innere Medizin II, Medizinische Universitätsklinik
Hugstetter Straße 55
79106 Freiburg
eMail: robert.thimme@uniklinik-freiburg.de
